A 50-year-old man with treatment-resistant depression has failed to respond to adequate trials of two SSRIs and one SNRI. After a collaborative discussion, the treatment plan includes transitioning to a monoamine oxidase inhibitor. He is currently taking a serotonergic antidepressant. The PMHNP is planning the medication transition. Which of the following best describes the critical safety consideration when planning this switch?